UNSPSC 51143222: Varenicline tartrate

This classification denotes a nicotinic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82269ASB48. European Medicines Agency schedules Varenicline tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22601. Varenicline tartrate generally arises in the molecular formula C13H13N3.C4H6O6. The term 'varenicline tartrate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule varenicline tartrate under HS 29333999 and SITC 51574.

As of Q4 2014, VARENICLINE TARTRATE remains US FDA's Preferred Term for this commodity. Varenicline tartrate bears US NLM identifiers UMLS ID C1711887 and NCI Concept Code C61998. SMILES: C1CNC2CC3C(CC2N1)[C@@H]4C[C@H]3CNC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51143222 Varenicline tartrate is a Commodity code for a specific smoking-cessation pharmaceutical product, but the recent state and local opportunities tagged under it do not align with varenicline procurement — the two posted solicitations concern naloxone and safe drug deactivation systems (Seminole County, Florida) and direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission). The code shows little relevant recent activity in state and local procurement for the product itself.

The Seminole County IFB (Solicitation IFB60459723LAS, response deadline July 26, 2023) is the only opportunity with concrete procurement substance, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS RFI (HHS0017013, posted April 3, 2026) is exploratory market research into direct-to-manufacturer prescription contracting models and does not constitute a demand signal for varenicline or any specific pharmaceutical product. Without recent, direct demand for varenicline tartrate in posted state and local solicitations, this code does not presently represent a pursuit opportunity for vendors focused on smoking-cessation pharmaceuticals.